Literature DB >> 15057898

Identification of discriminators of hepatoma by gene expression profiling using a minimal dataset approach.

Soek Ying Neo1, Chon Kar Leow, Vinsensius B Vega, Philip M Long, Amirul F M Islam, Paul B S Lai, Edison T Liu, Ee Chee Ren.   

Abstract

The severity of hepatocellular carcinoma (HCC) and the lack of good diagnostic markers and treatment strategies have rendered the disease a major challenge. Previous microarray analyses of HCC were restricted to the selected tissue sample sets without validation on an independent series of tissue samples. We describe an approach to the identification of a composite discriminator cassette by intersecting different microarray datasets. We studied the global transcriptional profiles of matched HCC tumor and nontumor liver samples from 37 patients using cDNA (cDNA) microarrays. Application of nonparametric Wilcoxon statistical analyses (P < 1 x 10(-6)) and the criteria of 1.5-fold differential gene expression change resulted in the identification of 218 genes, including BMI-1, ERBB3, and those involved in the ubiquitin-proteasome pathway. Elevated ERBB2 and epidermal growth factor receptor (EGFR) expression levels were detected in ERBB3-expressing tumors, suggesting the presence of ERBB3 cognate partners. Comparison of our dataset with an earlier study of approximately 150 tissue sets identified multiple overlapping discriminator markers, suggesting good concordance of data despite differences in patient populations and technology platforms. These overlapping discriminator markers could distinguish HCC tumor from nontumor liver samples with reasonable precision and the features were unlikely to appear by chance, as measured by Monte Carlo simulations. More significantly, validation of the discriminator cassettes on an independent set of 58 liver biopsy specimens yielded greater than 93% prediction accuracy. In conclusion, these data indicate the robustness of expression profiling in marker discovery using limited patient tissue specimens as well as identify novel genes that are highly likely to be excellent markers for HCC diagnosis and treatment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15057898     DOI: 10.1002/hep.20105

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  27 in total

1.  Role of Polycomb-group genes in sustaining activities of normal and malignant stem cells.

Authors:  Yoshihiro Takihara
Journal:  Int J Hematol       Date:  2007-11-30       Impact factor: 2.490

2.  Transcript AA454543 is a novel prognostic marker for hepatocellular carcinoma after curative partial hepatectomy.

Authors:  Siu Tim Cheung; Jenny C Y Ho; Ka Ling Leung; Xin Chen; Daniel Y T Fong; Samuel So; Sheung Tat Fan
Journal:  Neoplasia       Date:  2005-02       Impact factor: 5.715

3.  Global gene profiling of spontaneous hepatocellular carcinoma in B6C3F1 mice: similarities in the molecular landscape with human liver cancer.

Authors:  Mark J Hoenerhoff; Arun R Pandiri; Stephanie A Lahousse; Hu-Hua Hong; Tai-Vu Ton; Tiwanda Masinde; Scott S Auerbach; Kevin Gerrish; Pierre R Bushel; Keith R Shockley; Shyamal D Peddada; Robert C Sills
Journal:  Toxicol Pathol       Date:  2011-05-13       Impact factor: 1.902

4.  The homeobox gene HLXB9 is upregulated in a morphological subset of poorly differentiated hepatocellular carcinoma.

Authors:  Ludwig Wilkens; Rolf Jaggi; Caroline Hammer; Daniel Inderbitzin; Olivier Giger; Nils von Neuhoff
Journal:  Virchows Arch       Date:  2011-04-12       Impact factor: 4.064

5.  Genome-wide association study identifies three new susceptibility loci for esophageal squamous-cell carcinoma in Chinese populations.

Authors:  Chen Wu; Zhibin Hu; Zhonghu He; Weihua Jia; Feng Wang; Yifeng Zhou; Zhihua Liu; Qimin Zhan; Yu Liu; Dianke Yu; Kan Zhai; Jiang Chang; Yan Qiao; Guangfu Jin; Zhe Liu; Yuanyuan Shen; Chuanhai Guo; Jianhua Fu; Xiaoping Miao; Wen Tan; Hongbing Shen; Yang Ke; Yixin Zeng; Tangchun Wu; Dongxin Lin
Journal:  Nat Genet       Date:  2011-06-05       Impact factor: 38.330

6.  Akt phosphorylates the transcriptional repressor bmi1 to block its effects on the tumor-suppressing ink4a-arf locus.

Authors:  Yan Liu; Fan Liu; Hao Yu; Xinyang Zhao; Goro Sashida; Anthony Deblasio; Michael Harr; Qing-Bai She; Zhenbang Chen; Hui-Kuan Lin; Silvana Di Giandomenico; Shannon E Elf; Youyang Yang; Yasuhiko Miyata; Gang Huang; Silvia Menendez; Ingo K Mellinghoff; Neal Rosen; Pier Paolo Pandolfi; Cyrus V Hedvat; Stephen D Nimer
Journal:  Sci Signal       Date:  2012-10-23       Impact factor: 8.192

7.  Loss of hepatocyte ERBB3 but not EGFR impairs hepatocarcinogenesis.

Authors:  Lawrence A Scheving; Xiuqi Zhang; Mary C Stevenson; Michael A Weintraub; Annam Abbasi; Andrea M Clarke; David W Threadgill; William E Russell
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-10-22       Impact factor: 4.052

8.  Expression and clinicopathological significance of Mel-18 and Bmi-1 mRNA in gastric carcinoma.

Authors:  You-Wei Lu; Jin Li; Wei-Jian Guo
Journal:  J Exp Clin Cancer Res       Date:  2010-11-08

9.  Increased expression of ErbB-2 in liver is associated with hepatitis B x antigen and shorter survival in patients with liver cancer.

Authors:  Jie Liu; Angela Ahiekpor; Li Li; Xianxing Li; Patrick Arbuthnot; Michael Kew; Mark A Feitelson
Journal:  Int J Cancer       Date:  2009-10-15       Impact factor: 7.396

10.  JNK1 activation predicts the prognostic outcome of the human hepatocellular carcinoma.

Authors:  Qingshan Chang; Jianguo Chen; Kevin J Beezhold; Vince Castranova; Xianglin Shi; Fei Chen
Journal:  Mol Cancer       Date:  2009-08-17       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.